FDA panel backs Pfizer biosim to blockbuster anemia meds from Amgen, Johnson & Johnson

25th May 2017 Uncategorised 0

Pfizer’s biosimilar to blockbuster anemia meds—Amgen’s Epogen and Johnson & Johnson’s Procrit—won the support of an FDA expert panel on Thursday, moving another step closer to a potential approval.

More: FDA panel backs Pfizer biosim to blockbuster anemia meds from Amgen, Johnson & Johnson
Source: fierce